Cargando…

Cost-Effectiveness Analysis of a Once-Daily Single-Inhaler Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease (COPD) Using the FULFIL Trial: A Spanish Perspective

PURPOSE: To evaluate the cost-effectiveness of once-daily fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) vs twice-daily budesonide/formoterol (BUD/FOR) in patients with symptomatic chronic obstructive pulmonary disease (COPD) at risk of exacerbations, from the Spanish National Healthcare S...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schroeder, Melanie, Benjamin, Nicole, Atienza, Laura, Biswas, Chandroday, Martin, Alan, Whalen, John D, Izquierdo Alonso, José Luis, Riesco Miranda, Juan Antonio, Soler-Cataluña, Juan José, Huerta, Alicia, Ismaila, Afisi S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7360413/ https://www.ncbi.nlm.nih.gov/pubmed/32764908 http://dx.doi.org/10.2147/COPD.S240556

Ejemplares similares

Cost-Effectiveness of Once-Daily Single-Inhaler COPD Triple Therapy in Spain: IMPACT Trial
por: Paly, Victoria Federico, et al.
Publicado: (2022)

Once-Daily Triple Therapy in Patients with Advanced COPD: Healthcare Resource Utilization Data and Associated Costs from the FULFIL Trial
por: Ismaila, Afisi S., et al.
Publicado: (2017)

Cost-Effectiveness Of Once-Daily Single-Inhaler Triple Therapy In COPD: The IMPACT Trial
por: Ismaila, Afisi S, et al.
Publicado: (2019)

COPD Exacerbation Syndrome: The Spanish Perspective on an Old Dilemma
por: Soler-Cataluña, Juan Jose, et al.
Publicado: (2022)

A new approach to grading and treating COPD based on clinical phenotypes: summary of the Spanish COPD guidelines (GesEPOC)
por: Miravitlles, Marc, et al.
Publicado: (2013)

Cost-effectiveness analysis of a single-inhaler triple therapy for COPD in the UK
por: Fenwick, Elisabeth, et al.
Publicado: (2021)

Economic impact of delaying initiation with multiple-inhaler maintenance triple therapy in Spanish patients with chronic obstructive pulmonary disease
por: Sicras Mainar, Antoni, et al.
Publicado: (2019)

Is single-inhaler triple therapy for COPD cost-effective in the UK? The IMPACT trial
por: Martin, Alan, et al.
Publicado: (2022)

Impact of Single Combination Inhaler versus Multiple Inhalers to Deliver the Same Medications for Patients with Asthma or COPD: A Systematic Literature Review
por: Zhang, Shiyuan, et al.
Publicado: (2020)

Clinical effectiveness of once-daily fluticasone furoate/umeclidinium/vilanterol in usual practice: the COPD INTREPID study design
por: Worsley, Sally, et al.
Publicado: (2019)

Validation of the Spanish Activity Questionnaire in COPD (SAQ-COPD) in Patients with Chronic Obstructive Pulmonary Disease
por: Soler-Cataluña, Juan José, et al.
Publicado: (2022)

Impact of COPD Exacerbations and Burden of Disease in Spain: AVOIDEX Study
por: Soler-Cataluña, Juan José, et al.
Publicado: (2023)

Lack of Clinical Control in COPD Patients Depending on the Target and the Therapeutic Option
por: Soler-Cataluña, Juan José, et al.
Publicado: (2023)

Single-inhaler triple therapy in symptomatic COPD patients: FULFIL subgroup analyses
por: Halpin, David M.G., et al.
Publicado: (2018)

Characteristics of New Users of Single- and Multiple-Inhaler Triple Therapy for COPD in Primary Care in England
por: Rothnie, Kieran J, et al.
Publicado: (2022)

Preventing clinically important deterioration with single-inhaler triple therapy in COPD
por: Naya, Ian, et al.
Publicado: (2018)

The concept of control of COPD in clinical practice
por: Soler-Cataluña, Juan José, et al.
Publicado: (2014)

Clinical Control Criteria to Determine Disease Control in Patients with Severe COPD: The CLAVE Study
por: Soler-Cataluña, Juan José, et al.
Publicado: (2021)

Estimation of the Clinical and Economic Impact of an Improvement in Adherence Based on the Use of Once-Daily Single-Inhaler Triple Therapy in Patients with COPD
por: Miravitlles, Marc, et al.
Publicado: (2020)

Cost-Effectiveness of Single-Inhaler Triple Therapy (FF/UMEC/VI) versus Tiotropium Monotherapy in Patients with Symptomatic Moderate-to-Very Severe COPD in the UK
por: Kendall, Robyn, et al.
Publicado: (2023)

INTREPID: single- versus multiple-inhaler triple therapy for COPD in usual clinical practice
por: Halpin, David M.G., et al.
Publicado: (2021)

24-Hour Serial Spirometric Assessment of Once-Daily Fluticasone Furoate/Umeclidinium/Vilanterol Versus Twice-Daily Budesonide/Formoterol in Patients with COPD: Analysis of the FULFIL Study
por: Lipson, David A., et al.
Publicado: (2020)

Quantifying the Economic Impact of Delayed Multiple-Inhaler Triple Therapy Initiation in Patients with COPD: A Retrospective Cohort Study of Linked Electronic Medical Record and Hospital Administrative Data in England
por: Sansbury, Leah B, et al.
Publicado: (2021)

Health-related quality of life in outpatients with COPD in daily practice: the VICE Spanish study
por: Martín, Antonio, et al.
Publicado: (2008)

Effect of Recent Exacerbation History on the Efficacy of Once-Daily Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol Triple Therapy in Patients with Chronic Obstructive Pulmonary Disease in the FULFIL Trial
por: Panettieri Jr, Reynold A, et al.
Publicado: (2022)

Validation of clinical control in COPD as a new tool for optimizing treatment
por: Soler-Cataluña, Juan José, et al.
Publicado: (2018)

The dose of inhaled corticosteroids in patients with COPD: when less is better
por: Izquierdo, José Luis, et al.
Publicado: (2018)

DElaying Disease Progression In COPD with Early Initiation of Dual Bronchodilator or Triple Inhaled PharmacoTherapy (DEPICT): A Predictive Modelling Approach
por: Singh, Dave, et al.
Publicado: (2023)

Economic Burden of Chronic Obstructive Pulmonary Disease (COPD): A Systematic Literature Review
por: Iheanacho, Ike, et al.
Publicado: (2020)

Efficacy and Safety of Once-Daily Inhaled Umeclidinium in Asian Patients with COPD: Results from a Randomized, Placebo-Controlled Study
por: Zhong, Nanshan, et al.
Publicado: (2020)

A Delphi Consensus Document on the Use of Single-Inhaler Fixed-Dose Triple Therapies in COPD Patients
por: López-Campos, José Luis, et al.
Publicado: (2020)

Correction to: DElaying Disease Progression In COPD with Early Initiation of Dual Bronchodilator or Triple Inhaled PharmacoTherapy (DEPICT): A Predictive Modelling Approach
por: Singh, Dave, et al.
Publicado: (2023)

Cost-Effectiveness of Single- versus Multiple-Inhaler Triple Therapy in a UK COPD Population: The INTREPID Trial
por: Halpin, David M G, et al.
Publicado: (2022)

Is once enough? Understanding the preferences of COPD and asthma patients for once- versus twice-daily treatment
por: Horne, Rob
Publicado: (2013)

Benefit of Prompt versus Delayed Use of Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Following a COPD Exacerbation
por: Mannino, David, et al.
Publicado: (2022)

Unravelling young COPD and pre-COPD in the general population
por: Cosío, Borja G., et al.
Publicado: (2023)

Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD
por: Buhl, Roland, et al.
Publicado: (2012)

Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials
por: Ferguson, Gary T., et al.
Publicado: (2020)

Efficacy and safety of once-daily inhaled umeclidinium/vilanterol in Asian patients with COPD: results from a randomized, placebo-controlled study
por: Zheng, Jinping, et al.
Publicado: (2015)

Clinical, humanistic, and economic burden of chronic obstructive pulmonary disease (COPD) in Canada: a systematic review
por: Dang-Tan, Tam, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_75k3ge427slt32fj4dren89dlm